Erratum: Expression of myeloperoxidase and gene mutations in AML patients with normal karyotype: Double CEBPA mutations are associated with high percentage of MPO positivity in leukemic blasts (International Journal of Hematology (2011) 94 (81-89) DOI: 10.1007/s12185-011-0883-y);Expression of myeloperoxidase and gene mutations in AML patients with normal karyotype: Double CEBPA mutations are associated with high percentage of MPO positivity in leukemic blasts

International Journal of Hematology

Volumn 94, Issue 1, 2011, Pages 81-89

  Tominaga Sato, Shinya ^a   Tsushima, Hideki ^b   Ando, Koji ^c   Itonaga, Hidehiro ^a   Imaizumi, Yoshitaka ^b   Imanishi, Daisuke ^b   Iwanaga, Masako ^a   Taguchi, Jun ^a   Fukushima, Takuya ^b   Yoshida, Shinichiro ^c   Hata, Tomoko ^b   Moriuchi, Yukiyoshi ^d   Kuriyama, Kazutaka ^e   Mano, Hiroyuki ^f   Tomonaga, Masao ^g   Miyazaki, Yasushi ^a  

^a NAGASAKI UNIVERSITY GRADUATE SCHOOL OF BIOMEDICAL SCIENCES   (Japan)

^b NAGASAKI UNIVERSITY HOSPITAL   (Japan)

^c NATIONAL HOSPITAL ORGANIZATION NAGASAKI MEDICAL CENTER   (Japan)

^d Sasebo Shiritsu Sogo Hospital   (Japan)

^e UNIVERSITY OF THE RYUKYUS   (Japan)

^f JICHI MEDICAL UNIVERSITY   (Japan)

^g Japanese Red Cross Nagasaki Atomic Bomb Hospital Nagasaki   (Japan)

Author keywords

Acute myeloid leukemia; CEBPA mutations; Myeloperoxidase; Normal karyotype

Indexed keywords

CCAAT ENHANCER BINDING PROTEIN ALPHA; CD135 ANTIGEN; MYELOPEROXIDASE; NUCLEOPHOSMIN;

ACUTE GRANULOCYTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; BLAST CELL; BONE MARROW BIOPSY; CHROMOSOME ANALYSIS; CONFERENCE PAPER; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; GENE MUTATION; GENOTYPE; HIGH RISK PATIENT; HIGH RISK POPULATION; HUMAN; INTENSIVE CARE; KARYOTYPE; LEUKEMIA CELL; MAJOR CLINICAL STUDY; MALE; NUCLEOTIDE SEQUENCE; OVERALL SURVIVAL; PROGNOSIS; PROTEIN EXPRESSION; STATISTICAL SIGNIFICANCE; TREATMENT OUTCOME;

EID: 79960104568     PISSN: 09255710     EISSN: 18653774     Source Type: Journal    
DOI: 10.1007/s12185-012-1136-4     Document Type: Erratum

References (30)

1. S Miyawaki H Sakamaki S Ohtake N Emi F Yagasaki K Mitani 2005 A randomized, postremission comparison of four courses of standard-dose consolidation therapy without maintenance therapy versus three courses of standard-dose consolidation with maintenance therapy in adults with acute myeloid leukemia Cancer 104 2726 2734 (Pubitemid 41799616)
2. G David W Helen O Fiona W Keith H Christine H Georgina 1998 The importance of diagnostic cytogenetics on outcome in AML: analysis of 1, 612 patients entered into the MRC AML 10 trial Blood 92 2322 2333
3. S Ohtake S Miyawaki H Fujita H Kiyoi K Shinagawa N Usui 2011 Randomized study of induction therapy comparing standard-dose idarubicin with high-dose daunorubicin in adult patients with previously untreated acute myeloid leukemia: JALSG AML201 Study Blood 117 2358 2365
4. JM Bennett D Catovsky MT Daniel G Flandrin DA Galton HR Gralnick 1985 Proposed revised criteria for the classification of acute myeloid leukemia. A report of the French-American-British Cooperative Group Ann Intern Med 103 620 625
5. World Health Organization 2001
6. T Matsuo K Kuriyama Y Miyazaki S Yoshida M Tomonaga N Emi 2003 The percentage of myeloperoxidase-positive blast cells is a strong independent prognostic factor in acute myeloid leukemia, even in the patients with normal karyotype Leukemia 17 1538 1543 (Pubitemid 36986955)
7. J Taguchi Y Miyazaki C Tsutsumi Y Sawayama K Ando H Tsushima 2006 Expression of the myeloperoxidase gene in AC133 positive leukemia cells relates to the prognosis of acute myeloid leukemia Leuk Res 30 1105 1112 (Pubitemid 44037083)
8. Y Sawayama Y Miyazaki K Ando K Horio C Tsutsumi H Tsushima 2008 Expression of myeloperoxidase enhances the chemosensitivity of leukemia cells through the generation of reactive oxygen species and the nitration of protein Leukemia 22 956 964 (Pubitemid 351689877)
9. S Schnittger C Schoch W Kern C Mecucci C Tschulik MF Martelli 2005 Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype Blood 106 3733 3739 (Pubitemid 41739006)
10. N Boissel A Renneville V Biggio N Philippe X Thomas JM Cayuela 2005 Prevalence clinical profile, and prognosis of NPM mutations in AML with normal karyotype Blood 106 3618 3620 (Pubitemid 41609201)
11. M Yanada K Matsuo T Suzuki H Kiyoi T Naoe 2005 Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: a meta-analysis Leukemia 19 1345 1349 (Pubitemid 41136326)
12. C Preudhomme C Sagot N Boissel JM Cayuela I Tigaud S de Botton 2002 Favorable prognostic significance of CEBPA mutations in patients with de novo acute myeloid leukemia: a study from the Acute Leukemia French Association (ALFA) Blood 100 2717 2723
13. AF Gombart WK Hofmann S Kawano S Takeuchi U Krug SH Kwok 2002 Mutations in the gene encoding the transcription factor CCAAT/enhancer binding protein alpha in myelodysplastic syndromes and acute myeloid leukemias Blood 99 1332 1340 (Pubitemid 34547089)
14. RF Schlenk K Döhner J Krauter S Fröhling A Corbacioglu L Bullinger 2008 Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia N Engl J Med 358 1909 1918 (Pubitemid 351620111)
15. BJ Wouters B Löwenberg CA Erpelinck-Verschueren WL van Putten PJ Valk R Delwel 2009 Double CEBPA mutations, but not single CEBPA mutations, define a subgroup of acute myeloid leukemia with a distinctive gene expression profile that is uniquely associated with a favorable outcome Blood 113 3088 3091
16. A Dufour F Schneider KH Metzeler E Hoster S Schneider E Zellmeier 2010 Acute myeloid leukemia with biallelic CEBPA gene mutations and normal karyotype represents a distinct genetic entity associated with a favorable clinical outcome J Clin Oncol 28 570 577
17. S Miyawaki T Kobayashi M Tanimoto K Kuriyama H Murakami M Yoshida 1999 Comparison of leucopenia between cytarabine and behenoyl cytarabine in JALSG AML-89 consolidation therapy. The Japan Adult Leukemia Study Group Int J Hematol 70 56 57
18. S Miyawaki M Tanimoto T Kobayashi S Minami J Tamura E Omoto K Kuriyama 1999 No beneficial effect from addition of etoposide to daunorubicin, cytarabine, and 6-mercaptopurine in individualized induction therapy of adult acute myeloid leukemia: the JALSG-AML92 study. Japan Adult Leukemia Study Group Int J Hematol 70 97 104
19. S Ohtake S Miyawaki H Kiyoi Y Miyazaki H Okumura S Matsuda T Nagai 2010 Randomized trial of response-oriented individualized versus fixed-schedule induction chemotherapy with idarubicin and cytarabine in adult acute myeloid leukemia: the JALSG AML95 study Int J Hematol 91 276 283
20. H Kiyoi T Naoe Y Nakano S Yokota S Minami S Miyawaki 1999 Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia Blood 93 3074 3080 (Pubitemid 29200800)
21. B Falini C Mecucci E Tiacci M Alcalay R Rosati L Pasqualucci 2005 Cytoplasmic nucleophosmin in acute myelogenous leukemia with a normal karyotype N Engl J Med 352 254 266 (Pubitemid 40110814)
22. E Kaplan P Meier 1958 Nonparametric estimation from incomplete observations J Am Stat Assoc 53 457 462
23. C Yao Z Qin KN Works GE Austin AN Young 2008 CEBP and C-Myb sites are important for the functional activity of the human myeloperoxidase upstream enhancer Biochem Biophys Res Commun 371 309 314
24. K Reckzeh J Cammenga 2010 Molecular mechanisms underlying deregulation of C/EBPα in acute myeloid leukemia Int J Hematol 91 557 568
25. N Kato J Kitamura N Doki 2011 Two types of C/EBPα mutations play distincted but collaborative roles in leukemogenesis: lessons from clinical data and BMT models Blood 117 221 233
26. GE Austin WG Zhao A Regmi JP Lu J Braun 1998 Identification of an upstream enhancer containing an AML1 site in the human myeloperoxidase (MPO) gene Leuk Res 22 1037 1048 (Pubitemid 28454504)
27. PF Erickson M Robinson G Owens HA Drabkin 1994 The ETO portion of acute myeloid leukemia t(8;21) fusion transcript encodes a highly evolutionarily conserved, putative transcription factor Cancer Res 54 1782 1786 (Pubitemid 24116186)
28. S Meyers N Lenny SW Hiebert 1995 The t(8;21) fusion protein interferes with AML-1B-dependent transcriptional activation Mol Cell Biol 15 1974 1982
29. H Khoury BI Dalal SH Nantel DE Horsman JC Lavoie JD Shepherd 2004 Correlation between karyotype and quantitative immunophenotype in acute myelogenous leukemia with t(8;21) Modern Pathol 17 1211 1216 (Pubitemid 39312947)
30. H Shimada H Ichikawa M Ohki 2002 Potential involvement of the AML1-MTG8 fusion protein in the granulocytic maturation characteristic of the t(8;21) acute myelogenous leukemia revealed by microarray analysis Leukemia. 16 874 885 (Pubitemid 34537561)